enGene (ENGN) Projected to Post Earnings on Monday

enGene (NASDAQ:ENGN) is expected to be announcing its Q1 2026 results before the market opens on Monday, March 9th. Analysts expect enGene to post earnings of ($0.55) per share for the quarter. Individuals may visit the the company’s upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, March 12, 2026 at 4:00 PM ET.

enGene (NASDAQ:ENGN) last announced its quarterly earnings data on Monday, December 22nd. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.18). On average, analysts expect enGene to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

enGene Price Performance

Shares of ENGN stock opened at $10.11 on Monday. The company has a debt-to-equity ratio of 0.09, a current ratio of 6.30 and a quick ratio of 6.30. The company has a market capitalization of $677.27 million, a PE ratio of -4.41 and a beta of -0.29. The firm’s 50-day moving average is $9.57 and its two-hundred day moving average is $7.87. enGene has a 12 month low of $2.65 and a 12 month high of $12.25.

Wall Street Analyst Weigh In

ENGN has been the topic of a number of research analyst reports. Jefferies Financial Group initiated coverage on enGene in a research report on Friday, January 30th. They issued a “buy” rating and a $28.00 target price on the stock. Oppenheimer reaffirmed an “outperform” rating and set a $33.00 target price (up from $30.00) on shares of enGene in a research note on Wednesday, November 12th. HC Wainwright reissued a “buy” rating and issued a $25.00 price target on shares of enGene in a research note on Wednesday, December 3rd. Citigroup restated a “market outperform” rating on shares of enGene in a report on Monday, January 5th. Finally, Citizens Jmp lifted their target price on shares of enGene from $18.00 to $21.00 and gave the company a “market outperform” rating in a report on Wednesday, November 12th. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $23.29.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the business. Cresset Asset Management LLC acquired a new stake in enGene during the 2nd quarter worth approximately $36,000. Paloma Partners Management Co acquired a new stake in shares of enGene in the second quarter valued at $38,000. Raymond James Financial Inc. boosted its holdings in enGene by 383.6% in the third quarter. Raymond James Financial Inc. now owns 10,000 shares of the company’s stock valued at $68,000 after purchasing an additional 7,932 shares during the period. Jump Financial LLC purchased a new position in enGene in the fourth quarter valued at $121,000. Finally, Millennium Management LLC grew its stake in enGene by 57.3% during the 3rd quarter. Millennium Management LLC now owns 20,502 shares of the company’s stock worth $140,000 after purchasing an additional 7,472 shares in the last quarter. Institutional investors and hedge funds own 64.16% of the company’s stock.

About enGene

enGene, Inc is a clinical‐stage biopharmaceutical company focused on the development of gene‐based therapeutics for oncology. The company’s core technology is the EnGene Delivery Vehicle (EDV) platform, which employs nonliving, bacterially derived minicells to transport therapeutic payloads directly to tumor cells. By combining targeted delivery with potent payloads, enGene aims to improve the precision and efficacy of cancer treatments while reducing off‐target toxicity.

Through its EDV platform, enGene has advanced multiple therapeutic candidates into preclinical and clinical stages.